Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21

Am J Hematol. 2021 Jul 1;96(7):E253-E257. doi: 10.1002/ajh.26191. Epub 2021 May 3.

Christoph R Kimmich^{1

2

3}, Tobias Terzer⁴, Axel Benner⁴, Timon Hansen⁵, Alexander Carpinteiro⁶, Tobias Dittrich^{1

2}, Kaya Veelken^{1

2}, Anna Jauch⁷, Stefanie Huhn¹, Marco Basset^{1

2

8

9}, Hartmut Goldschmidt^{1

10}, Carsten Müller-Tidow¹, Stefan O Schönland^{1

2}, Ute Hegenbart^{1

2}

¹ Division of Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
² Amyloidosis Center, Heidelberg University Hospital, Heidelberg, Germany.
³ Department of Oncology and Hematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany.
⁴ Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁵ Hematology/Oncology practice, Hämatologisch-Onkologische Praxis Altona, Hamburg, Germany.
⁶ Department of Hematology, University Hospital Essen, Essen, Germany.
⁷ Institute of Human Genetics, University Heidelberg, Heidelberg, Germany.
⁸ Amyloidosis Research and Treatment Center, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
⁹ Department of Molecular Medicine, University of Pavia, Pavia, Italy.
¹⁰ National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.

No abstract available

Publication types